Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis

doi:10.3748/wjg.v18.i8.767

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

(0)

(11302)

(69)

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Brief Article

World J Gastroenterol. Feb 28, 2012; 18(8): 767-777
Published online Feb 28, 2012. doi: 10.3748/wjg.v18.i8.767

Full Size Figure Download Figure

Figure 2 Efficacy of rifaximin vs oral disaccharides, rifaximin vs other oral antibiotics and rifaximin vs control therapy which included the combination of oral disaccharides and other antibiotics. M-H: Mantel Haenszel.

Citation: Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis. World J Gastroenterol 2012; 18(8): 767-777
URL: https://www.wjgnet.com/1007-9327/full/v18/i8/767.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i8.767

Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis. World J Gastroenterol 2012; 18(8): 767-777 [PMID: 22371636 DOI: 10.3748/wjg.v18.i8.767]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.